Ms. Deardorf has more than 25 years of international biotechnology leadership experience across a range of companies and therapeutic areas. She currently serves as Chief Commercial Officer of Magenta Therapeutics, a clinical-stage company, where she is responsible for crafting and executing the commercial strategy for their pipeline of novel transplant therapies. Prior to this she served as the Chief Commercial Officer of Ohana Biosciences developing commercial strategy for fundraising and business development efforts, including planning for the company’s first commercial product launch.
Previously, she held a variety of commercial roles of increasing responsibility at Biogen, most recently leading and executing a highly successful global launch of SPINRAZA® for a rare condition SMA. She was the US Lead for Biogen’s 1st ALS Product Dexpramipexole, which despite failure in phase 3, gave her a passion and commitment for rare diseases. In her tenure at Biogen, Caren was instrumental in building the MS franchise at Biogen helping to establish their global leadership through US and Global brand management including the launches of TECFIDERA, TYSABRI and AVONEX. Caren also serves on the Board of Directors for the Pan Mass Challenge, a non-profit organization that has raised over $750 Million for the Dana Farber Center Institute.
Ms. Deardorf holds an MBA from Babson College and a Bachelor of Science degree in Biology from Tufts University.